Guobang Pharma (SH:605507)2024-10-18 07:56Financial Performance - The company's operating revenue for Q3 2024 reached ¥1,525,790,635.53, representing a year-on-year increase of 22.68%[2] - Net profit attributable to shareholders for the same period was ¥174,287,031.37, up 32.43% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥169,797,536.14, reflecting a growth of 35.19% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.31, an increase of 29.17% from the same period last year[3] - Total operating revenue for the first nine months of 2024 reached ¥4,418,147,150.19, an increase from ¥4,053,476,803.52 in the same period last year, representing a growth of approximately 9.0%[13] - Net profit for the first nine months of 2024 was ¥578,638,198.06, compared to ¥487,655,739.51 in the previous year, indicating a growth of approximately 18.7%[14] - Operating profit improved to ¥673,947,665.53 from ¥563,975,837.46, marking an increase of around 19.5%[14] - The total comprehensive income for the period was ¥578,638,198.06, up from ¥487,655,739.51, indicating an increase of approximately 18.7%[14] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥10,633,387,010.99, showing a 2.62% increase from the end of the previous year[3] - As of September 30, 2024, the total assets of Guobang Pharmaceutical Group Co., Ltd. amounted to approximately CNY 10.63 billion, an increase from CNY 10.36 billion as of December 31, 2023, representing a growth of about 2.6%[9] - The total current liabilities rose to CNY 2.56 billion from CNY 2.45 billion, indicating an increase of approximately 4.4%[10] - The total liabilities decreased to ¥2,787,527,931.11 from ¥2,924,446,559.57, a reduction of approximately 4.7%[11] - Total equity attributable to shareholders increased to ¥7,840,370,923.66 from ¥7,432,033,896.40, reflecting a growth of about 5.5%[11] Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 201.75% to ¥32,877,901.61[5] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 32,877,901.61, compared to CNY 10,895,807.14 in the same period of 2023, indicating a significant increase[16] - Total cash inflow from operating activities reached CNY 3,400,423,392.91, up from CNY 3,105,919,536.32 year-over-year[16] - Total cash outflow from operating activities was CNY 3,367,545,491.30, compared to CNY 3,095,023,729.18 in the same period last year[16] - The net cash flow from financing activities was -CNY 151,036,711.84, an improvement from -CNY 164,313,936.32 in the same period last year[16] Shareholder Information - The company reported a total of 28,241 common shareholders at the end of the reporting period[6] - The largest shareholder, Xinchang Ander Trading Co., Ltd., holds 23.08% of the shares[6] - The company has not reported any significant changes in its major shareholders or their participation in financing activities during the reporting period[8] Expenses and Costs - Total operating costs increased to ¥3,724,615,529.84 from ¥3,478,553,568.83, reflecting a rise of about 7.1%[13] - Research and development expenses were ¥160,287,477.94, slightly down from ¥162,761,109.22, showing a decrease of about 1.5%[13] - The company reported a financial expense of -¥8,334,127.17, a significant improvement compared to -¥44,897,282.10 in the previous year[13] Cash and Equivalents - The company's cash and cash equivalents decreased to CNY 1.48 billion from CNY 2.09 billion, reflecting a decline of approximately 29.4%[9] - Cash and cash equivalents at the end of the period were CNY 1,195,933,856.89, down from CNY 1,523,212,082.84 at the end of the third quarter of 2023[16] - The company received CNY 3,225,232,628.53 in cash from sales of goods and services, compared to CNY 2,792,847,209.49 in the previous year, reflecting a growth of approximately 15.5%[15]